Seminars in Hematology
Volume 44, Issue 1 , Pages 24-31, January 2007

Transfusion-Associated Microchimerism: A New Complication of Blood Transfusions in Severely Injured Patients

  • William Reed

      Affiliations

    • Blood Systems Research Institute, San Francisco, CA.
    • Department of Laboratory Medicine, University of California, San Francisco, CA.
    • Corresponding Author InformationAddress correspondence to William Reed, MD, Blood Systems Research Institute, 270 Masonic Ave, San Francisco, CA 94118.
  • ,
  • Tzong-Hae Lee

      Affiliations

    • Blood Systems Research Institute, San Francisco, CA.
  • ,
  • Philip J. Norris

      Affiliations

    • Blood Systems Research Institute, San Francisco, CA.
    • Department of Laboratory Medicine, University of California, San Francisco, CA.
    • Department of Medicine, University of California, San Francisco, CA.
  • ,
  • Garth H. Utter

      Affiliations

    • Department of Surgery, University of California, Davis, Medical Center (UCDMC), Sacramento, CA.
  • ,
  • Michael P. Busch

      Affiliations

    • Blood Systems Research Institute, San Francisco, CA.
    • Department of Laboratory Medicine, University of California, San Francisco, CA.

Microchimerism, the stable persistence of an allogeneic cell population, can result from allogeneic exposures including blood transfusion. Transfusion-associated microchimerism (TA-MC) appears to be a common but newly recognized complication of blood transfusion. Thus far TA-MC has been detected when severely injured patients are transfused. Injury induces an immunosuppressive and inflammatory milieu in which fresh blood products with replication-competent leukocytes can sometimes cause TA-MC. TA-MC is present in approximately half of transfused severely injured patients at hospital discharge and is not affected by leukoreduction. In approximately 10% of patients, the chimerism from a single blood donor may increase in magnitude over months to years, reaching as much as 2% to 5% of all circulating leukocytes. In this review, we discuss recent studies of TA-MC in the civilian trauma population and the potential for study of TA-MC in the military population, where the severity of injury and freshness of blood products suggest that TA-MC may be even more prominent. We also discuss the need for future studies to address the immunology of TA-MC, its stem cell biology, and its clinical manifestations that have the potential to be either pathologic (autoimmunity, graft-versus-host disease) or therapeutic (tolerance induction, various cell and gene therapies).

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by grant R01-HL-083388 and a Specialized Center of Research (SCOR) grant in Transfusion Medicine from the National Heart Lung and Blood Institute (P50-HL-54476), and in part by a grant from the Blood Systems Foundation, Scottsdale, AZ.

PII: S0037-1963(06)00234-4

doi:10.1053/j.seminhematol.2006.09.012

Seminars in Hematology
Volume 44, Issue 1 , Pages 24-31, January 2007